Table 2.

Maximum toxicity per patient during the dose limiting toxicity evaluation period (n = 6)

Adverse event	NCI-CTC grade
	All grades, n (%)	≥ Grade 3, n (%)
Hematologic
Leukopenia	0 (0)	0 (0)
Neutropenia	0 (0)	0 (0)
Thrombocytopenia	0 (0)	0 (0)
AST increased	1 (17)	0 (0)
ALT increased	1 (17)	1 (17)
Hypoalbuminemia	2 (33)	0 (0)
Hypokalemia	2 (33)	0 (0)
Hyponatremia	1 (17)	1 (17)
Hypomagnesemia	2 (33)	0 (0)
Non-hematologic
Alopecia	2 (33)	–
Anorexia	3 (50)	0 (0)
Conjunctivitis	1 (17)	0 (0)
Constipation	1 (17)	0 (0)
Diarrhea	4 (67)	0 (0)
Dry skin	2 (33)	0 (0)
Fatigue	1 (17)	0 (0)
Febrile neutropenia	0 (0)	0 (0)
Infusion-related reaction	1 (17)	0 (0)
Malaise	3 (50)	–
Nausea	3 (50)	0 (0)
Palpitations	1 (17)	0 (0)
Peripheral sensory neuropathy	3 (50)	0 (0)
Pruritus	1 (17)	0 (0)
Rash acneiform	3 (50)	0 (0)
Stomatitis	2 (33)	0 (0)
Vomiting	1 (17)	0 (0)
Weight loss	1 (17)	0 (0)

NCI-CTC National Cancer Institute Common Toxicity Criteria, AST aspartate transaminase, ALT, alanine transaminase